BOSTON, Sept. 2, 2020 /PRNewswire/ -- NeuroBo
Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage
biotechnology company focused on developing and commercializing
multimodal, disease-modifying therapies for neurodegenerative and
cardiometabolic diseases, today announced that Douglas J. Swirsky, President and Chief
Executive Officer of publicly traded Rexahn Pharmaceuticals, Inc.,
has been appointed to the Company's Board of Directors, effective
September 1, 2020. In addition to his
position as an independent director, Mr. Swirsky will also serve as
a member of the Audit Committee. He replaces Steven Gullans, Ph.D., who resigned from the
Board of Directors effective August 31,
2020.
"Doug brings to Neurobo more than two decades of relevant
experience in the biopharmaceutical and healthcare sectors, having
served as a director of, or in senior management positions at, a
number of publicly held companies over the last 14 years and having
provided counsel to corporate clients as a healthcare investment
banker," stated Richard J. Kang,
Ph.D., President and Chief Executive Officer of NeuroBo. "Doug's
vast industry expertise and proven leadership capabilities make him
a valuable asset, and we look forward to working together on our
clinical and preclinical pipeline activities. As we welcome Doug to
the NeuroBo team, I want to also extend our sincere gratitude to
Dr. Gullans for his service on the Board and his contributions to
our merger with Gemphire."
In addition to his roles at Rexahn, Mr. Swirsky is currently
Chairman of the Board of Cellectar Biosciences, Inc., a publicly
traded, clinical stage biopharmaceutical company. Prior to joining
Rexahn in January 2018, from 2013
through its sale to Precigen, Inc. (formerly known as Intrexon
Corporation) in 2017, Mr. Swirsky was President and Chief Executive
Officer of publicly traded biotechnology company, GenVec, Inc.,
which he joined in 2006 as Chief Financial Officer. Prior to
joining GenVec, Mr. Swirsky worked at Stifel Nicolaus, where he
served as a managing director and the head of Life Sciences
Investment Banking. Previously, Mr. Swirsky held investment banking
positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason.
Mr. Swirsky is a certified public accountant and a CFA®
charterholder. He received his B.S. in Business Administration from
Boston University and his M.B.A. from
the Kellogg School of Management at Northwestern University.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is focused on novel treatments for neurodegenerative and
cardiometabolic diseases affecting millions of patients worldwide.
The company's multimodal approach has the potential to address the
multiple underlying mechanisms of neurodegenerative diseases,
alleviate symptoms and slow disease progression. The company's drug
candidate, NB-01, for the treatment of painful diabetic neuropathy
(PDN), has been shown in a Phase 2 study to significantly reduce
pain symptoms associated with PDN with a superior safety profile
when compared to currently available treatments. Due to global
COVID-19 crisis, a planned Phase 3 study was postponed. In the
interim, NeuroBo is exploring a potential orphan drug indication
targeting chronic pain for NB-01. NeuroBo's drug candidate, NB-02,
is focused on the treatment of Alzheimer's disease and
neurodegenerative diseases associated with the pathological
dysfunction of tau proteins in the brain. The company's third
program, Gemcabene, is focused on developing and commercializing
therapies for the treatment of dyslipidemia, a serious medical
condition that increases the risk of life-threatening
cardiovascular disease.
NeuroBo Pharmaceuticals was jointly founded by Dr. Roy
Freeman, professor of neurology at Harvard Medical
School and renowned expert in neuropathic pain, and JK
BioPharma Solutions, a biotechnology consulting company, to
commercialize natural product-based research into ethical
medicines. In December 2019, NeuroBo
merged with Gemphire Therapeutics and through such merger, became
listed on the Nasdaq Stock Market and added the Gemcabene family of
related assets to its portfolio. For more information
visit: https://www.neurobopharma.com.
Contacts:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:http://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-appoints-douglas-j-swirsky-to-the-board-of-directors-301122677.html
SOURCE NeuroBo Pharmaceuticals, Inc.